This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
PDE 4 Inhibitor
Drug Names(s): Phosphodiesterase 4 inhibitor
Deal Structure: The Celltech Group, the original developer of PDE 4, was acquired by UCB S.A. for approximately $1.9 billion on May 18th, 2004.
Partners: Merck & Co., Inc.
PDE 4 Inhibitor News
Additional information available to subscribers only: